Invitro International

Invitro International EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Invitro International (IVRO) as of Oct 11, 2026 is 87,018.00 USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 68,301.00 USD — a change of 27.40% (higher).

EBITDA

87,018.00USD

YoY

27.40%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Invitro International is 2025 87,018.00 USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Invitro International was 2024 68,301.00 USD. It decreases by 27.40% higher compared to the previous year.

The Invitro International EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
40,717.00 USD
Jan 1, 2019
60,580.00 USD
Jan 1, 2020
31,290.00 USD
Jan 1, 2021
-26,790.00 USD
Jan 1, 2022
-116,770.00 USD
Jan 1, 2023
-25,340.00 USD
Jan 1, 2024
68,301.00 USD
Jan 1, 2025
87,018.00 USD
The Invitro International EBITDA history
YEAREBITDAYoY
87,018.00USD+27.40%
68,301.00USD-369.54%
-25,340.00USD-78.30%
-116,770.00USD+335.87%
-26,790.00USD-185.62%
31,290.00USD-48.35%
60,580.00USD+48.78%
40,717.00USD-64.96%
116,205.00USD—
Access this data via the Eulerpool API

Invitro International Stock analysis

What does Invitro International do? Invitro International is a leading company in the development of cell and tissue cultures as well as test systems for the pharmaceutical, cosmetic, and biotechnology industry. The company was founded in 1982 by Dr. George K. J. Uehara, a renowned scientist and specialist in the field of cell culture technology. His aim was to create a reliable alternative to animal testing to meet the industry's need for safe and effective test systems. Invitro International offers a wide range of products, including cell cultures and tissue samples derived from human or animal tissue. These are of the highest quality and are manufactured under strict quality controls. The tissue cultures are obtained from living organs and are ideal for the development of new drugs and cosmetics, as well as for studying the effects of environmental toxins and chemicals. Another focus of Invitro International is the development of test systems tailored to the needs of customers. These can include in vitro tests on cell and tissue cultures, as well as molecular analysis and screening methods. The company is divided into various industries and sectors, including pharmaceutical research, toxicology, cosmetics industry, biotechnology, and environmental research. Each of these sectors is supervised by specialized scientists and experts who have in-depth knowledge and experience in their respective fields. Invitro International places great emphasis on environmentally friendly and ethical standards in the development of new test systems and products. The company is also involved in various initiatives to promote alternatives to animal testing and actively advocates for the protection and welfare of animals. One of Invitro International's most well-known products is the Eye Irritation Test System (EITS), which is widely used in the cosmetics industry. It is a reliable in vitro test that determines the eye irritation potentials of new products based on human tissue. Invitro International has become a leading company in the field of cell culture technology and is now known worldwide for its high-quality products and services. The company takes pride in offering its customers safe, effective, and environmentally friendly test systems and is committed to continuing to develop innovative solutions to meet the industry's requirements. Invitro International is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invitro International stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Invitro International is 87,018.00 USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Invitro International changed from 68,301.00 USD to 87,018.00 USD, representing a 27.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Invitro International since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Invitro International historically and in real time.

Access this data via the Eulerpool API

Income Statement — Invitro International

All Key Metrics — Invitro International